Journal ArticleDOI
The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Jason Gotlib,Jason Gotlib,Jason Gotlib,Jan Cools,Jan Cools,Jan Cools,James M. Malone,James M. Malone,James M. Malone,Stanley L. Schrier,Stanley L. Schrier,Stanley L. Schrier,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland,Steven Coutre,Steven Coutre,Steven Coutre +17 more
Reads0
Chats0
TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).About:
This article is published in Blood.The article was published on 2004-04-15. It has received 264 citations till now. The article focuses on the topics: Chronic eosinophilic leukemia & Hypereosinophilic syndrome.read more
Citations
More filters
Journal ArticleDOI
IgE, Mast Cells, Basophils, and Eosinophils
TL;DR: This review highlights what is known about mast cells, basophils, and eosinophils and their roles in disease pathogenesis and central effector cells in allergic inflammation.
Journal ArticleDOI
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
TL;DR: A clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.
Journal ArticleDOI
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
TL;DR: The current state of understanding of the genetic basis of AML and MPD is described, with a specific focus on pathogenetic and therapeutic significance.
Journal ArticleDOI
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
TL;DR: Improved understanding of the role of PDGF signaling in tumor biology, and the introduction ofPDGF antagonists, has set the stage for a continued development of PD GF antagonists as novel cancer drugs.
Journal ArticleDOI
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Kathryn G. Roberts,Zhaohui Gu,Debbie Payne-Turner,Kelly McCastlain,Richard C. Harvey,I-Ming Chen,Deqing Pei,Ilaria Iacobucci,Marcus B. Valentine,Stanley Pounds,Lei Shi,Yongjin Li,Jinghui Zhang,Cheng Cheng,Alessandro Rambaldi,Manuela Tosi,Orietta Spinelli,Jerald P. Radich,Mark D. Minden,Jacob M. Rowe,Selina M. Luger,Mark R. Litzow,Martin S. Tallman,Peter H. Wiernik,Ravi Bhatia,Ibrahim Aldoss,Jessica Kohlschmidt,Krzysztof Mrózek,Guido Marcucci,Clara D. Bloomfield,Wendy Stock,Stephen Kornblau,Hagop M. Kantarjian,Marina Konopleva,Elisabeth Paietta,Cheryl L. Willman,Charles G. Mullighan +36 more
TL;DR: Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome, and trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph- like ALL.
References
More filters
Journal ArticleDOI
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Seiichi Hirota,Koji Isozaki,Yasuhiro Moriyama,Koji Hashimoto,Toshirou Nishida,Shingo Ishiguro,Kiyoshi Kawano,Masato Hanada,Akihiko Kurata,Masashi Takeda,Ghulam Muhammad Tunio,Yuji Matsuzawa,Yuzuru Kanakura,Yasuhisa Shinomura,Yukihiko Kitamura +14 more
TL;DR: Sequencing of c-kit complementary DNA from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains, suggesting that the mutations contribute to tumor development.
Journal ArticleDOI
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Michael Heinrich,Christopher L. Corless,Anette Duensing,Laura McGreevey,Chang Jie Chen,Nora E. Joseph,Samuel Singer,Diana J. Griffith,Andrea Haley,Ajia Town,George D. Demetri,Christopher D.M. Fletcher,Jonathan A. Fletcher,Jonathan A. Fletcher +13 more
TL;DR: Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression, suggesting KIT and PDGFra mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.
Journal ArticleDOI
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more
TL;DR: The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Journal ArticleDOI
The roles of FLT3 in hematopoiesis and leukemia.
TL;DR: Results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene, and preliminary studies suggest that mutantFLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.
Journal ArticleDOI
The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.
TL;DR: A group of 14 patients had hematologic, cardiac, and neurologic abnormalities attributable to this disease, and patient survival and response to chemotherapy was significantly better in this group than in previously reported patients.
Related Papers (5)
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more